Circulating tumor cells (CTCs) are specialized rare cells, which have been shed from a primary solid tumor of the body and circulate in the vasculature system of the body, eventually causing metastasis. CTCs act as the seeds for successive development of additional metastatic tumors in distant organs, which is liable for the majority of cancer-related deaths. On the other hand, these fatal rare cells are capable of providing useful information of cancer patients, since their monitoring and detection is valuable for predicting the response to treatment and prognosis as well as staging of the disease.
麻豆原创 Analysis and Insights: Global Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创
The global Circulating Tumor Cells (CTCs) Prognostic Technologies market is projected to grow from US$ 1720.8 million in 2023 to US$ 3959.6 million by 2029, at a Compound Annual Growth Rate (CAGR) of 14.9% during the forecast period.
The US & Canada market for Circulating Tumor Cells (CTCs) Prognostic Technologies is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Circulating Tumor Cells (CTCs) Prognostic Technologies is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Circulating Tumor Cells (CTCs) Prognostic Technologies is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key companies of Circulating Tumor Cells (CTCs) Prognostic Technologies include AdnaGen, ACDBio, Celula, Epic Sciences, Fluxion Biosciences, Rarecells, Silicon Biosystems and Vitatex, etc. in 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Circulating Tumor Cells (CTCs) Prognostic Technologies market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Circulating Tumor Cells (CTCs) Prognostic Technologies, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Circulating Tumor Cells (CTCs) Prognostic Technologies, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Circulating Tumor Cells (CTCs) Prognostic Technologies revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Circulating Tumor Cells (CTCs) Prognostic Technologies market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Circulating Tumor Cells (CTCs) Prognostic Technologies revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including AdnaGen, ACDBio, Celula, Epic Sciences, Fluxion Biosciences, Rarecells, Silicon Biosystems and Vitatex, etc.
By Company
AdnaGen
ACDBio
Celula
Epic Sciences
Fluxion Biosciences
Rarecells
Silicon Biosystems
Vitatex
Segment by Type
Tumor Cell Enrichment
Tumor Cell Detection
Segment by Application
Prostate Cancer
Breast Cancer
Colorectal Cancer
Lung Cancer
Ovarian Cancer
Pancreatic Cancer
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Circulating Tumor Cells (CTCs) Prognostic Technologies in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Circulating Tumor Cells (CTCs) Prognostic Technologies companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Circulating Tumor Cells (CTCs) Prognostic Technologies revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Tumor Cell Enrichment
1.2.3 Tumor Cell Detection
1.3 麻豆原创 by Application
1.3.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Prostate Cancer
1.3.3 Breast Cancer
1.3.4 Colorectal Cancer
1.3.5 Lung Cancer
1.3.6 Ovarian Cancer
1.3.7 Pancreatic Cancer
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Perspective (2018-2029)
2.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Growth Trends by Region
2.2.1 Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Circulating Tumor Cells (CTCs) Prognostic Technologies Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Dynamics
2.3.1 Circulating Tumor Cells (CTCs) Prognostic Technologies Industry Trends
2.3.2 Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Drivers
2.3.3 Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Challenges
2.3.4 Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Circulating Tumor Cells (CTCs) Prognostic Technologies by Players
3.1.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue by Players (2018-2023)
3.1.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Circulating Tumor Cells (CTCs) Prognostic Technologies, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Concentration Ratio
3.4.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Circulating Tumor Cells (CTCs) Prognostic Technologies Revenue in 2022
3.5 Global Key Players of Circulating Tumor Cells (CTCs) Prognostic Technologies Head office and Area Served
3.6 Global Key Players of Circulating Tumor Cells (CTCs) Prognostic Technologies, Product and Application
3.7 Global Key Players of Circulating Tumor Cells (CTCs) Prognostic Technologies, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Circulating Tumor Cells (CTCs) Prognostic Technologies Breakdown Data by Type
4.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted 麻豆原创 Size by Type (2024-2029)
5 Circulating Tumor Cells (CTCs) Prognostic Technologies Breakdown Data by Application
5.1 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Circulating Tumor Cells (CTCs) Prognostic Technologies Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size (2018-2029)
6.2 North America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Type
6.2.1 North America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Type (2018-2023)
6.2.2 North America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Type (2024-2029)
6.2.3 North America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Share by Type (2018-2029)
6.3 North America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Application
6.3.1 North America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Application (2018-2023)
6.3.2 North America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Application (2024-2029)
6.3.3 North America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Share by Application (2018-2029)
6.4 North America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Country
6.4.1 North America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Country (2018-2023)
6.4.3 North America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size (2018-2029)
7.2 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Type
7.2.1 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Type (2018-2023)
7.2.2 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Type (2024-2029)
7.2.3 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Share by Type (2018-2029)
7.3 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Application
7.3.1 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Application (2018-2023)
7.3.2 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Application (2024-2029)
7.3.3 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Share by Application (2018-2029)
7.4 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Country
7.4.1 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Country (2018-2023)
7.4.3 Europe Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size (2018-2029)
8.2 China Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Type
8.2.1 China Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Type (2018-2023)
8.2.2 China Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Type (2024-2029)
8.2.3 China Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Share by Type (2018-2029)
8.3 China Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Application
8.3.1 China Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Application (2018-2023)
8.3.2 China Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Application (2024-2029)
8.3.3 China Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size (2018-2029)
9.2 Asia Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Type
9.2.1 Asia Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Type (2018-2023)
9.2.2 Asia Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Type (2024-2029)
9.2.3 Asia Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Share by Type (2018-2029)
9.3 Asia Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Application
9.3.1 Asia Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Application (2018-2023)
9.3.2 Asia Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Application (2024-2029)
9.3.3 Asia Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Share by Application (2018-2029)
9.4 Asia Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Region
9.4.1 Asia Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Region (2018-2023)
9.4.3 Asia Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size (2018-2029)
10.2 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Circulating Tumor Cells (CTCs) Prognostic Technologies 麻豆原创 Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 AdnaGen
11.1.1 AdnaGen Company Details
11.1.2 AdnaGen Business Overview
11.1.3 AdnaGen Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.1.4 AdnaGen Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2018-2023)
11.1.5 AdnaGen Recent Developments
11.2 ACDBio
11.2.1 ACDBio Company Details
11.2.2 ACDBio Business Overview
11.2.3 ACDBio Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.2.4 ACDBio Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2018-2023)
11.2.5 ACDBio Recent Developments
11.3 Celula
11.3.1 Celula Company Details
11.3.2 Celula Business Overview
11.3.3 Celula Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.3.4 Celula Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2018-2023)
11.3.5 Celula Recent Developments
11.4 Epic Sciences
11.4.1 Epic Sciences Company Details
11.4.2 Epic Sciences Business Overview
11.4.3 Epic Sciences Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.4.4 Epic Sciences Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2018-2023)
11.4.5 Epic Sciences Recent Developments
11.5 Fluxion Biosciences
11.5.1 Fluxion Biosciences Company Details
11.5.2 Fluxion Biosciences Business Overview
11.5.3 Fluxion Biosciences Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.5.4 Fluxion Biosciences Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2018-2023)
11.5.5 Fluxion Biosciences Recent Developments
11.6 Rarecells
11.6.1 Rarecells Company Details
11.6.2 Rarecells Business Overview
11.6.3 Rarecells Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.6.4 Rarecells Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2018-2023)
11.6.5 Rarecells Recent Developments
11.7 Silicon Biosystems
11.7.1 Silicon Biosystems Company Details
11.7.2 Silicon Biosystems Business Overview
11.7.3 Silicon Biosystems Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.7.4 Silicon Biosystems Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2018-2023)
11.7.5 Silicon Biosystems Recent Developments
11.8 Vitatex
11.8.1 Vitatex Company Details
11.8.2 Vitatex Business Overview
11.8.3 Vitatex Circulating Tumor Cells (CTCs) Prognostic Technologies Introduction
11.8.4 Vitatex Revenue in Circulating Tumor Cells (CTCs) Prognostic Technologies Business (2018-2023)
11.8.5 Vitatex Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
AdnaGen
ACDBio
Celula
Epic Sciences
Fluxion Biosciences
Rarecells
Silicon Biosystems
Vitatex
听
听
*If Applicable.
